Anti-Vascular Endothelial Growth Factor Treatment Compared with Steroid Treatment for Retinal Vein Occlusion: A Meta-Analysis

to related objects

Background: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) and steroid treatment are both used for macular edema (ME) secondary to retinal vein occlusion (RVO), however a continual reevaluation of their comparative efficacy is required. Objectives: This meta-analysis aimed to compare the efficacy and safety of intravitreal anti-VEGF agents and intravitreal steroids for the treatment of ME secondary to RVO. Methods: A systematic literature search was conducted on Ovid MEDLINE, EMBASE, and the Cochrane Controlled Register of Trials for studies published between January 2005 and November 2021. Randomized controlled trials (RCTs) reporting on patients with ME secondary to RVO who were treated with intravitreal steroids or anti-VEGF agents were included. A random effects meta-analysis was performed. Results: 879 eyes from 11 RCTs were included. At the last study observation, intravitreal anti-VEGF agents were associated with a significantly better best corrected visual acuity (WMD = −0.14 logMAR, 95% CI = [−0.19, −0.09], p < 0.00001) and lower retinal thickness (WMD = −38.01 µm, 95% CI = [−56.17, −19.85], p < 0.0001) relative to intravitreal steroids. Similar findings were found at 3–12 month time points. Intravitreal anti-VEGF agents were associated with a significantly lower incidence of IOP-related adverse events (RR = 0.28, 95% CI = [0.15, 0.51], p < 0.0001), cataract development/progression (RR = 0.22, 95% CI = [0.09, 0.49], p = 0.0003), and conjunctival hemorrhage (RR = 0.52, 95% CI = [0.32, 0.86], p = 0.01). Conclusions: Our meta-analysis found superiority of intravitreal anti-VEGF agents relative to intravitreal steroids for the treatment of ME secondary to RVO with regards to visual acuity, anatomic outcomes, and safety endpoints.

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
Anti-Vascular Endothelial Growth Factor Treatment Compared with Steroid Treatment for Retinal Vein Occlusion: A Meta-Analysis ; volume:245 ; number:6 ; year:2023 ; pages:500-515 ; extent:16
Ophthalmologica ; 245, Heft 6 (2023), 500-515 (gesamt 16)

Creator
Patil, Nikhil S.
Hatamnejad, Amin
Mihalache, Andrew
Popovic, Marko M.
Kertes, Peter J.
Muni, Rajeev H.

DOI
10.1159/000527626
URN
urn:nbn:de:101:1-2023020823161825217838
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Patil, Nikhil S.
  • Hatamnejad, Amin
  • Mihalache, Andrew
  • Popovic, Marko M.
  • Kertes, Peter J.
  • Muni, Rajeev H.

Other Objects (12)

Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion

Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion

Treatment of Branch Retinal Vein Occlusion induced Macular Edema with Bevacizumab

Treatment of Branch Retinal Vein Occlusion induced Macular Edema with Bevacizumab

Treatment outcomes of retinal vein occlusion in clinical practice in Nepal

Treatment outcomes of retinal vein occlusion in clinical practice in Nepal

Clinical Features and Treatment Outcome of a Concurrent Central Retinal Vein Occlusion and Cilioretinal Artery Occlusion

Clinical Features and Treatment Outcome of a Concurrent Central Retinal Vein Occlusion and Cilioretinal Artery Occlusion

Time to initiate anti-vascular endothelial growth factor therapy and visual outcome in central retinal vein occlusion

Time to initiate anti-vascular endothelial growth factor therapy and visual outcome in central retinal vein occlusion

Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy

Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy

Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion

Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion

Percutaneous Endovascular Sapheno‑Femoral Bypass for Treatment of Chronic Iliac Vein Stent Occlusion

Percutaneous Endovascular Sapheno‑Femoral Bypass for Treatment of Chronic Iliac Vein Stent Occlusion

Intravitreal Dexamethasone Implant Has Better Retinal Perfusion than Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion: A Five-Year Real-World Study

Intravitreal Dexamethasone Implant Has Better Retinal Perfusion than Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion: A Five-Year Real-World Study

Covid-19 Impact on Macular Neovascularization and Retinal Vein Occlusion Treatment: Single-Center Experience

Covid-19 Impact on Macular Neovascularization and Retinal Vein Occlusion Treatment: Single-Center Experience

Treatment responses for branch retinal vein occlusion predicted by semi-automated fluorescein angiography quantification

Treatment responses for branch retinal vein occlusion predicted by semi-automated fluorescein angiography quantification

Risk of retinal vein occlusion in colorectal cancer patients receiving anti-vascular endothelial growth factors – a population-based cohort study

Risk of retinal vein occlusion in colorectal cancer patients receiving anti-vascular endothelial growth factors – a population-based cohort study

Related objects